Literature DB >> 26810884

The shadow of inequitable conduct in the US patent application.

Bao-Chi Chang1, Shyh-Jen Wang2,3.   

Abstract

Inequitable conduct regarding any single claim can render the entire patent unenforceable and further damage other related patents and applications in the assignee's patent portfolio. The adverse impact of inequitable conduct significantly became a litigation strategy. The US Federal Circuit (CAFC) observed that inequitable conduct as a patent litigation strategy had become a plague and thus tightened the standard for finding inequitable conduct in a case with full court judges. However, under the shadow of previous adverse impact of inequitable conduct, patent applicants may still submit many marginal related references. This study demonstrates that an applicant even prepared an information disclosure statement (IDS) as many as 50 pages. Actually, under the new standard, inequitable conduct would not further produce significant impact in the US patent system. Thus, a patent applicant need not submit marginal references but should distinguish the prior art from the current application, especially for those listed in the IDS, to avoid the novelty rejection.

Keywords:  inequitable conduct; information disclosure statement; intent; materiality; patent portfolio

Mesh:

Year:  2016        PMID: 26810884      PMCID: PMC4963061          DOI: 10.1080/21645515.2015.1121339

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  6 in total

1.  Patent portfolios for biotech inventions.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2013-06       Impact factor: 54.908

2.  The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.

Authors:  Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

3.  The obviousness rejection as a barrier to biotech patent prosecution.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2009-12       Impact factor: 54.908

4.  The written description rejection as a barrier to biotech patent prosecution.

Authors:  Shyh-Jen Wang
Journal:  Hum Vaccin       Date:  2011-05-01

Review 5.  The obviousness rejection as a barrier to vaccine patent prosecution.

Authors:  Shyh-Jen Wang
Journal:  Hum Vaccin       Date:  2011-04

Review 6.  Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.

Authors:  Timothy J Price; Eva Segelov; Matthew Burge; Daniel G Haller; Niall C Tebbutt; Christos S Karapetis; Cornelis J A Punt; Nick Pavlakis; Dirk Arnold; Peter Gibbs; Jeremy D Shapiro
Journal:  Expert Rev Anticancer Ther       Date:  2014-08-20       Impact factor: 4.512

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.